In his doctoral thesis he stated that CP was a result of a problem around the time of birth. He later identified a difficult delivery, a preterm birth and perinatal asphyxia in particular as risk factors. The spastic diplegia form of CP came to be known as Littles disease. At around this time, a German surgeon was also working on cerebral palsy, and distinguished it from polio. In the 1880s British neurologist William Gowers built on Littles work by linking paralysis in newborns to difficult births. He named the problem "birth palsy" and classified birth palsies into two types: peripheral and cerebral.Working in Pennsylvania in the 1880s, Canadian-born physician William Osler (1849–1919) reviewed dozens of CP cases to further classify the disorders by the site of the problems on the body and by the underlying cause. Osler made further observations tying problems around the time of delivery with CP, and concluded that problems causing bleeding inside the brain were likely the root cause. Osler also suspected polioencephalitis as an infectious cause. Through the 1890s, scientists commonly confused CP with polio.Before moving to psychiatry, Austrian neurologist Sigmund Freud (1856–1939) made further refinements to the classification of the disorder. He produced the system still being used today. Freuds system divides the causes of the disorder into problems present at birth, problems that develop during birth, and problems after birth.
Chemistry
Testosterone enanthate, or testosterone 17β-heptanoate, is a synthetic androstane steroid and a derivative of testosterone. It is an androgen ester; specifically, it is the C17β enanthate (heptanoate) ester of testosterone. History
Testosterone enanthate was described as early as 1952 and was first introduced for medical use in the United States in 1954 under the brand name Delatestryl. Society and culture
Generic names
Testosterone enanthate is the generic name of the drug and its USAN and BAN. It has also referred to as testosterone heptanoate. Brand names
Testosterone enanthate is marketed primarily under the brand name Delatestryl.It is or has been marketed under a variety of other brand names as well, including, among others:
Andro LA
Andropository
Cypionat
Cypoprime
Depandro
Durathate
Everone
Testocyp
Testostroval
Testrin
Testro LA
Xyosted
pharmaqo labs

Availability
Testosterone enanthate is available in the United States and widely elsewhere throughout the world. Testosterone enanthate (testosterone heptanoate) is often available in concentrations of 200 mg per milliliter of fluid. Legal status
Testosterone enanthate, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act and a schedule IV controlled substance in Canada under the Controlled Drugs and Substances Act. Research
As of October 2017, an auto-injection formulation of testosterone enanthate was in preregistration for the treatment of hypogonadism in the United States. Xyosted
On October 1, 2018, the U.S. Food and Drug Administration (FDA) announced the approval of Xyosted. Xyosted, a product of Antares Pharma, Inc., is a single-use disposable auto-injector that dispenses testosterone enanthate. Xyosted is the first FDA-approved subcutaneous testosterone enanthate product for testosterone replacement therapy in adult males. == References ==